An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Bicycle Therapeutics to Present at the 2023 AACR Annual Meeting
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the company will present four poster presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting, taking place in Orlando, FL on April 14-19, 2023.
Poster Presentation Details:
Title: Modulation of natural killer cell immune response to tumor with novel synthetic tumor-immune cell agonist, NK-TICA™
Session Title: Immunomodulatory Agents and Interventions 1
Date and Time:Monday, April 17, 2023 at 9:00 a.m. ET Abstract Number: 1806
Speaker/Lead Author: Fay Dufort, Bicycle Therapeutics
Title: Development of in vivo models for evaluation of NK-TICA™, novel Bicycle® tumor-targeted immune cell agonist® designed to engage NK cells
Session Title: Immunomodulatory Agents and Interventions 1
Date and Time:Monday, April 17, 2023 at 9:00 a.m. ET Abstract Number: 1826
Speaker/Lead Author:Lukas Stanczuk, Bicycle Therapeutics
Title: EphA2-dependent CD137 agonism and anti-tumor efficacy by BT7455, a Bicycle® tumor-targeted immune cell agonist®
Session Title: Immunomodulatory Agents and Interventions 2
Date and Time:Monday, April 17, 2023 at 9:00 a.m. ET Abstract Number: 1832
Speaker/Lead Author:Lia Luus, Bicycle Therapeutics
Title: Phase 1/2 study of the safety, pharmacokinetics, and preliminary clinical activity of BT7480 in patients with Nectin-4 associated advanced malignancies
Session Title: Phase I and First-in-Human Clinical Trials in Progress
Date and Time:Tuesday, April 18, 2023 at 1:30 p.m. ET Abstract Number: CT253
Speaker/Lead Author:Thomas R. Jeffry Evans, MBBS: School of Cancer Sciences, University of Glasgow
The posters will be made available on the Publications section of bicycletherapeutics.com following the presentations.
About Bicycle Therapeutics
Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC™) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA™ targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, MA. For more information, visit bicycletherapeutics.com.
bicycle therapeutics is a biotechnology company with big ambitions. we aim to revolutionise the pharmaceutical landscape with our disruptive technology and proprietary bicyclic peptide (bicycle®) product platform and to develop transformational new therapies for patients to improve future treatment options in oncology. bicycles, a new class of small molecular weight drug conjugates for oncology and other diseases, are designed to have superior targeting abilities and to be more efficacious and better tolerated than existing drug conjugate modalities. they combine the properties of several therapeutic entities in a single modality, exhibiting the affinity and selective pharmacology associated with antibodies; the distribution kinetics of small molecules, allowing rapid tumor penetration; and the “tuneable” pharmacokinetic half-life and renal clearance of peptides, sparing cytotoxin-payload derived liver and gastrointestinal toxicity. our unique ip is based on the work of scientific foun
